Greenwich LifeSciences (GLSI) vs Vicore Pharma AB (VCRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Greenwich LifeSciences is the larger company by market cap ($282.6 million vs $264.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | VCRE |
|---|---|---|
| Share price | $19.25 | $9.41 |
| Market cap | $282.56M | $264.89M |
| 1-day change | -2.73% | -5.09% |
| YTD return | -8.38% | — |
| 1-year return | +136.20% | — |
| 5-year return | -41.84% | — |
| EPS (TTM) | $-1.63 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-19.36M | — |
| 52-week high | $34.10 | $17.80 |
| 52-week low | $7.78 | $7.88 |
| Distance from 52-week high | -43.55% | -47.16% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +198.70% | +158.90% |
| Average volume | 160.76K | 23.31K |
| Shares outstanding | 14.68M | 28.16M |
| Employees | — | 50 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About Vicore Pharma AB
VCRE stock →Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 50 employees
GLSI vs VCRE FAQ
Which is bigger, Greenwich LifeSciences or Vicore Pharma AB?
Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $282.56M compared with $264.89M for Vicore Pharma AB (VCRE).
Are Greenwich LifeSciences and Vicore Pharma AB in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.